A Phase II, Open Label, Extension Study to Assess the Effect of PRO044 in Patients With Duchenne Muscular Dystrophy

Trial Profile

A Phase II, Open Label, Extension Study to Assess the Effect of PRO044 in Patients With Duchenne Muscular Dystrophy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs BMN 044 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioMarin Nederland; BioMarin Pharmaceutical
  • Most Recent Events

    • 31 May 2016 According to a BioMarin media release, the company intends to discontinue clinical and regulatory development of Kyndrisa as well as the three other first-generation follow-on products, BMN 044, BMN 045 and BMN 053, currently in Phase 2 studies for distinct forms of Duchenne muscular dystrophy.
    • 31 May 2016 Status changed from recruiting to discontinued, according to a BioMarin media release.
    • 31 Mar 2015 New source identified and integrated (European Clinical Trials Database record; EudraCT2013-003605-26).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top